菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

In vivo studies often present challenges in evaluating T cell engagers (TCEs) due to their complex MOA and pharmacology. Reliable interpretation of PK/PD, efficacy, and safety data requires rational study design and fit-for-purpose models to improve translational relevance.

 

This webinar will introduce multiple in vivo models across species (cynomolgus NHPs, hFcRn mice, human PBMC/CDX models) for translational evaluation of TCE exposure-response relationships. Through detailed case studies, you will gain practical insights into TMDD-driven nonlinear clearance and associated PK/PD responses in NHP studies, dose-dependent toxicity, and correlating tissue T cell infiltration and translational PK studies, helping to refine study design, mitigate preclinical risks, and streamline the path toward clinical success.

 

In this webinar, you will discover:

 

  • Rational study design to align preclinical models with PBMC/CDX models for TCEs
  • Key considerations for selecting optimal species and models to maximize translational relevance
  • Interpretation of unique TCE exposure-response patterns and histological datasets to support go/no-go decisions
  • Proactive troubleshooting to overcome preclinical challenges and maintain accelerated timelines

 

 

Webinar Details

 

Date: Thursday, April 16, 2026

Time: 9:00 AM PT | 12:00 PM ET | 5:00 PM BST

 

Speaker:

 

Zhili Yao, Ph.D.

Zhili Yao, Ph.D.

Director, CRO Services

Dr. Zhili Yao is the Director of the In Vivo Pharmacology Group in WuXi Biologics’ CRO Services Department. He earned his degree from the Department of Chemistry and Biochemistry at Ohio State University, followed by three years of training as immunologist at the Wexner Medical Center. With over 10 years’ experience in macromolecular PK/PD/Tox platforms and oncology & autoimmune disease models, Dr. Yao played a key role in establishing the NHP toxicokinetics platform and the murine antibody biodistribution platform. Dr. Yao has also led the in vivo studies for multiple key IND projects, several of which have successfully advanced to the clinical stage.

Enter your information to watch the recording

 

 

 

 

Have specific questions about in vivo pharmacology?

Reach out to our experts!

Your Project. Our Expertise.